We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pembrolizumab in combination with chemotherapy in patients with advanced squamous cell lung cancer -- clinical trials and real-world data.
- Authors
Knetki-Wróblewska, Magdalena; Kowalski, Dariusz M.
- Abstract
Advanced squamous-cell lung carcinoma remains a disease with an unfavorable prognosis. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was limited. Implementation of immune check-point inhibitors allowed for an improvement in treatment results. The KEYNOTE-407 study included patients with squamous-cell lung cancer who received 4 immunochemotherapy cycles followed by maintenance treatment with pembrolizumab. Median overall survival of 17.2 months versus 11.6 months for chemotherapy was obtained (risk of death reduction by 29%) while the percentage of patients remaining in follow-up was 18%. Analysis of patients with good performance status treated in clinical practice confirms the results from the registration study and emphasizes the importance of taking into consideration clinical factors while qualifying patients for treatment.
- Subjects
PEMBROLIZUMAB; CANCER chemotherapy; SQUAMOUS cell carcinoma; LUNG cancer; CLINICAL trials
- Publication
Oncology in Clinical Practice (2450-1654), 2024, Vol 20, Issue 3, p209
- ISSN
2450-1654
- Publication type
Article
- DOI
10.5603/OCP.2023.0047